Similarly, CXCR4-targeted PEGylated PLGA NPs could co-deliver sorafenib and metapristone (chemopreventive agent targeting SDF-1/CXCR4 axis) into HCC in vitro and in vivo, thereby enhancing cytotoxicity and synergistically suppressing HCC proliferation and resistance (Zheng et al., 2019). The gene discussed is CXCL12; the disease is hepatocellular carcinoma.